TAK-915

TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment[1][2].

Product Specifications

CAS Number

[1476727-50-0]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tak-915.html

Purity

99.57

Solubility

DMSO : 7.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N1)CN(C(N[C@@H](C2=CC(F)=C(OC(F)(F)F)C=C2)COC)=O)C3=C1C=C(OC)C=N3

Molecular Formula

C19H18F4N4O5

Molecular Weight

458.36

References & Citations

[1]Mikami S, et al. Discovery of Clinical Candidate N- ((1S) -1- (3-Fluoro-4- (trifluoromethoxy) phenyl) -2-methoxyethyl) -7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4 (1H) -carboxamide (TAK-915) : A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. J Med Chem. 2017 Sep 28;60 (18) :7677-7702.|[2]Nakashima M, et al. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models. Behav Brain Res. 2019 Dec 30;376:112192.